High expression of KLK14 in prostatic adenocarcinoma is associated with elevated risk of prostate-specific antigen relapse

Tumor Biology

Volumn 29, Issue 1, 2008, Pages 1-8

  Rabien, Anja ^a   Fritzsche, Florian ^a   Jung, Monika ^a   Diamandis, Eleftherios P ^b   Loening, Stefan A ^a   Dietel, Manfred ^a   Jung, Klaus ^a   Stephan, Carsten ^a   Kristiansen, Glen ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Immunohistochemistry; Kallikreins; KLK14; Prostate cancer; Real time reverse transcription polymerase chain reaction

Indexed keywords

MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; PROTEIN; PROTEIN KLK14;

ADULT; AGED; ARTICLE; CANCER RELAPSE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; PROTEIN EXPRESSION;

EID: 44349148355     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000132565     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Chatterjee SK, Zetter BR: Cancer biomarkers: knowing the present and predicting the future. Future Oncol 2005;1:37-50.
3. Lundwall A, Band V, Blaber M, Clements JA, Courty Y, Diamandis EP, Fritz H, Lilja H, Malm J, Maltais LJ, Olsson AY, Petraki C, Scorilas A, Sotiropoulou G, Stenman UH, Stephan C, Talieri M, Yousef GM: A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol Chem 2006;387:637-641.
4. Borgono CA, Diamandis EP: The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004;4:876-890.
5. Borgono CA, Michael IP, Shaw JL, Luo LY, Ghosh MC, Soosaipillai A, Grass L, Katsaros D, Diamandis EP: Expression and functional characterization of the cancer-related serine protease, human tissue kallikrein 14. J Biol Chem 2007;282:2405-2422.
6. Paliouras M, Borgono C, Diamandis EP: Human tissue kallikreins: the cancer biomarker family. Cancer Lett 2007;249:61-79.
7. Stephan C, Jung K, Nakamura T, Yousef GM, Kristiansen G, Diamandis EP: Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer. Int J Urol 2006;13:238-243.
8. Hooper JD, Bui LT, Rae FK, Harvey TJ, Myers SA, Ashworth LK, Clements JA: Identification and characterization of KLK14, a novel kallikrein serine protease gene located on human chromosome 19q13.4 and expressed in prostate and skeletal muscle. Genomics 2001;73:117-122.
9. Yousef GM, Magklara A, Chang A, Jung K, Katsaros D, Diamandis EP: Cloning of a new member of the human kallikrein gene family, KLK14, which is down-regulated in different malignancies. Cancer Res 2001;61:3425-3431.
10. Felber LM, Borgono CA, Cloutier SM, Kundig C, Kishi T, Ribeiro CJ, Jichlinski P, Gygi CM, Leisinger HJ, Diamandis EP, Deperthes D: Enzymatic profiling of human kallikrein 14 using phage-display substrate technology. Biol Chem 2005;386:291-298.
11. Borgono CA, Grass L, Soosaipillai A, Yousef GM, Petraki CD, Howarth DH, Fracchioli S, Katsaros D, Diamandis EP: Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. Cancer Res 2003;63:9032-9041.
12. Yousef GM, Fracchioli S, Scorilas A, Borgono CA, Iskander L, Puopolo M, Massobrio M, Diamandis EP, Katsaros D: Steroid hormone regulation and prognostic value of the human kallikrein gene 14 in ovarian cancer. Am J Clin Pathol 2003;119:346-355.
13. Fritzsche F, Gansukh T, Borgono CA, Burkhardt M, Pahl S, Mayordomo E, Winzer KJ, Weichert W, Denkert C, Jung K, Stephan C, Dietel M, Diamandis EP, Dahl E, Kristiansen G: Expression of human kallikrein 14 (KLK14) in breast cancer is associated with higher tumour grades and positive nodal status. Br J Cancer 2006;94:540-547.
14. Komatsu N, Takata M, Otsuki N, Toyama T, Ohka R, Takehara K, Saijoh K: Expression and localization of tissue kallikrein mRNAs in human epidermis and appendages. J Invest Dermatol 2003;121:542-549.
15. Stefansson K, Brattsand M, Ny A, Glas B, Egelrud T: Kallikrein-related peptidase 14 may be a major contributor to trypsin-like proteolytic activity in human stratum corneum. Biol Chem 2006;387:761-768.
16. Yousef GM, Stephan C, Scorilas A, Ellatif MA, Jung K, Kristiansen G, Jung M, Polymeris ME, Diamandis EP: Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues. Prostate 2003;56:287-292.
17. Yousef GM, Polymeris ME, Yacoub GM, Scorilas A, Soosaipillai A, Popalis C, Fracchioli S, Katsaros D, Diamandis EP: Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res 2003;63:2223-2227.
18. Yousef GM, Borgono CA, Scorilas A, Ponzone R, Biglia N, Iskander L, Polymeris ME, Roagna R, Sismondi P, Diamandis EP: Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis. Br J Cancer 2002;87:1287-1293.
19. Sobin LH, Wittekind C: TNM Classification of Malignant Tumours, ed 5. New York, Wiley-Liss, 1997.
20. Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen C, Thrasher JB, Thompson I: Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007;177:540-545.
21. Jung K, Stephan C, Lein M, Henke W, Schnorr D, Brux B, Schurenkamper P, Loening SA: Analytical performance and clinical validity of two free prostate-specific antigen assays compared. Clin Chem 1996;42:1026-1033.
22. Xu C, Jung M, Burkhardt M, Stephan C, Schnorr D, Loening S, Jung K, Dietel M, Kristiansen G: Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy. Prostate 2005;62:224-232.
23. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3:research0034.1-research 0034.11.
24. Ohl F, Jung M, Xu C, Stephan C, Rabien A, Burkhardt M, Nitsche A, Kristiansen G, Loening SA, Radonic A, Jung K: Gene expression studies in prostate cancer tissue: which reference gene should be selected for normalization? J Mol Med 2005;83:1014-1024.
25. Naito S: Evaluation and management of prostate-specific antigen recurrence after radical prostatectomy for localized prostate cancer. Jpn J Clin Oncol 2005;35:365-374.
26. Petraki CD, Papanastasiou PA, Karavana VN, Diamandis EP: Cellular distribution of human tissue kallikreins: immunohistochemical localization. Biol Chem 2006;387:653-663.
27. Yousef GM, Diamandis EP: Human tissue kallikreins: a new enzymatic cascade pathway? Biol Chem 2002;383:1045-1057.
28. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, Zattoni F: EAU Guidelines on Prostate Cancer. Eur Urol 2008;53:68-80.
29. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW: Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294:433-439.
30. Grubb RL 3rd, Andriole GL: Can preoperative PSA doubling time and PSA velocity predict outcomes following radical prostatectomy? Nat Clin Pract Urol 2006;3:306-307.
31. Maffezzini M, Bossi A, Collette L: Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer. Eur Urol 2007;51:605-613.